Gapping up
In reaction to strong earnings/guidance:
- BLFS +17.5%, OMER +14.6%, HTZ +12.9%, AYTU +12.7%, RGSE +12.2%, ZSAN +11.4%, ATEC +10.3%, VJET +10.1%, IMMU +9.9%, (also Board of Directors has voted to appoint Michael Pehl as President and Chief Executive Officer, effective December 7), WTT +9.9%, GROW +9.8%, TRXC +9%, CATB +8.5%, ESEA +7.8%, SGYP +7.1%, AVID +6.4%, ANY +6%, SNOA +5.5%, (also files for $75 mln mixed securities shelf offering), SNOA +5.5%, TRTC +5%, CTSO +4.8%, NVDA +4.6%, MT +4.6%, JYNT +4.4%, CDXC +4.3%, DDS +4.2%, AYX +4.2%, SPRT +4%, CLMT +3.6%, NAO +3.6%, XXII +2.9%, NH +2.9%, ENDP +2.5%, ZOES +2.4%, ARGS +2.4%, APVO +2%, (also enters into Equity Distribution Agreement under which it may issue and sell through Piper Jaffray shares of common stock having an aggregate offering price of up to $17.5 mln ) APVO +2%, RIBT +1.9%, BDSI +1.8%, JAGX +1.7%, TRIL +1.7%, PULM +1.3%, UEPS +1.2%, LOMA +1.1%, KLDX +1%, VUZI +0.9%, NWSA +0.8%, DIS +0.8%
M&A news:
- EA +0.8% (Electronic Arts to acquire Respawn Entertainment for $151 mln in cash and up to $164 mln in the form of restricted stock units; expected to be neutral to EA's net income in 2018 and 2019)
Other news:
- DVAX +15.5% (announces the FDA has approved HEPLISAV-B for prevention of Hepatitis B in adults)
- ATOS +5.3% (Iroquois Capital Management discloses 9.01% passive stake)
- THS +4.4% (will webcast Investor Day presentation on Monday November 13 - will discuss the the strategy, operations and TreeHouse 2020 initiatives)
- CAR +4.1% (following HTZ results)
- MDR +1.8% ( announces a 'major' contract award from a Middle East customer)
- AMD +1.5% (following NVDA results)
- WDC +1.2% (announced an authorization to resume potential repurchases of its common stock under a previously approved $5 bln repurchase program by its board)
- PANW +1% (rebounding after closing 9+ pts lower)
Analyst comments:
- VKTX +2.3% (resumed with a Buy at H.C. Wainwright; tgt $7 (stock closed at 2.19 on Thur))
- AAN +1.4% (upgraded to Strong Buy from Mkt Perform at Raymond James)
- UBS +1.2% (upgraded to Buy from Neutral at BofA/Merrill)
- CVS +1.2% (upgraded to Buy at Needham)
